Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 8 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2021 Filed Feb 23, 2021 23:03 UTC |
GRAHAM RICHARD ASVP, Development
|
Tax withholdingOrdinary Shares | 6,597 | $18.79 | $123,957.63 |
DisclosureSEC source: 0001179110-21-002154 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,152 Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:01 UTC |
BRADY ANNPresident, TBIL
|
Tax withholdingOrdinary Shares | 10,092 | $18.79 | $189,628.68 |
DisclosureSEC source: 0001179110-21-002152 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,195 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:55 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001542 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,395 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:46 UTC |
PITZER KENNETH RSVP, Prod Strat & Comm Plng
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001538 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,280 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:51 UTC |
Shafer Bradford JEVP, Gen. Counsel, Secretary
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001540 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,916 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:53 UTC |
Winningham Rick EDirector · Chief Executive Officer
|
GrantOrdinary Shares | 170,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001541 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,445,169 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:48 UTC |
SABESAN VIJAYSVP, Technical Operations
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001539 · edgar.xml · nonDerivative · entry 1 SABESAN VIJAY · CIK 0001767807 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,044 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:30 UTC |
GRAHAM RICHARD ASVP, Development
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001543 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,749 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:45 UTC |
PASQUALONE FRANKSVP, Chief Business Officer
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001537 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,680 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:43 UTC |
Hindman Andrew A.SVP, Chief Financial Officer
|
GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001536 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,688 F1 · balance_after: Includes 553 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 13, 2020. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:39 UTC |
BRADY ANNPresident, TBIL
|
GrantOrdinary Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001535 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,287 Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 23:09 UTC |
GRAHAM RICHARD ASVP, Development
|
SaleOrdinary Shares | 7,500 | $19.47 | $146,058.00 |
DisclosureSEC source: 0001179110-20-012003 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,749 F1 · price: This transaction was executed in multiple trades at prices from $19.46 to $19.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 18:42 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
SaleOrdinary Shares | 4,246 | $18.00 | $76,428.00 |
DisclosureSEC source: 0001179110-20-011737 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,395 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:25 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011379 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,641 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:19 UTC |
PITZER KENNETH RSVP, Prod Strat & Comm Plng
|
Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011371 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,280 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:22 UTC |
Shafer Bradford JEVP, Gen. Counsel, Secretary
|
Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011375 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,916 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:24 UTC |
Winningham Rick EDirector · Chief Executive Officer
|
Tax withholdingOrdinary Shares | 13,946 | $17.21 | $240,010.66 |
DisclosureSEC source: 0001179110-20-011377 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,169 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:21 UTC |
SABESAN VIJAYSVP, Technical Operations
|
Tax withholdingOrdinary Shares | 3,798 | $17.21 | $65,363.58 |
DisclosureSEC source: 0001179110-20-011373 · edgar.xml · nonDerivative · entry 1 SABESAN VIJAY · CIK 0001767807 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,044 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:17 UTC |
PASQUALONE FRANKSVP, Chief Comm Ops Officer
|
Tax withholdingOrdinary Shares | 4,214 | $17.21 | $72,522.94 |
DisclosureSEC source: 0001179110-20-011369 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,680 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:16 UTC |
HAUMANN BRETT KChief Medical Officer
|
Tax withholdingOrdinary Shares | 4,639 | $17.21 | $79,837.19 |
DisclosureSEC source: 0001179110-20-011367 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,171 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:14 UTC |
GRAHAM RICHARD ASVP, Development
|
Tax withholdingOrdinary Shares | 3,876 | $17.21 | $66,705.96 |
DisclosureSEC source: 0001179110-20-011365 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,249 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:13 UTC |
BRADY ANNPresident, TBIL
|
Tax withholdingOrdinary Shares | 2,292 | $17.21 | $39,445.32 |
DisclosureSEC source: 0001179110-20-011363 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,287 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:10 UTC |
GRAHAM RICHARD ASVP, Development
|
GrantOrdinary Shares | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009566 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,125 Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 22:21 UTC |
HAUMANN BRETT KChief Medical Officer
|
SaleOrdinary Shares | 25,000 | $18.29 | $457,240.00 |
DisclosureSEC source: 0001179110-20-009263 · edgar.xml · nonDerivative · entry 2 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,810 F1 · price: This transaction was executed in multiple trades at prices from $18.22 to $18.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:38 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009277 · edgar.xml · nonDerivative · entry 2 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,448 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:38 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
SaleOrdinary Shares | 17,103 | $18.00 | $307,854.00 |
DisclosureSEC source: 0001179110-20-009277 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,252 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:29 UTC |
PITZER KENNETH RSVP, Prod Strat & Comm Plng
|
Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009269 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,087 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:34 UTC |
Shafer Bradford JEVP, Gen. Counsel, Secretary
|
Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009273 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,723 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:36 UTC |
Winningham Rick EDirector · Chief Executive Officer
|
Tax withholdingOrdinary Shares | 13,946 | $18.22 | $254,096.12 |
DisclosureSEC source: 0001179110-20-009275 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,289,115 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:32 UTC |
SABESAN VIJAYSVP, Technical Operations
|
Tax withholdingOrdinary Shares | 3,799 | $18.22 | $69,217.78 |
DisclosureSEC source: 0001179110-20-009271 · edgar.xml · nonDerivative · entry 1 SABESAN VIJAY · CIK 0001767807 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,842 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:27 UTC |
PASQUALONE FRANKSVP, Chief Comm Ops Officer
|
Tax withholdingOrdinary Shares | 4,214 | $18.22 | $76,779.08 |
DisclosureSEC source: 0001179110-20-009267 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,894 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:24 UTC |
Hindman Andrew A.SVP, Chief Financial Officer
|
Tax withholdingOrdinary Shares | 4,323 | $18.22 | $78,765.06 |
DisclosureSEC source: 0001179110-20-009265 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,135 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:21 UTC |
HAUMANN BRETT KChief Medical Officer
|
Tax withholdingOrdinary Shares | 4,646 | $18.22 | $84,650.12 |
DisclosureSEC source: 0001179110-20-009263 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,810 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:20 UTC |
GRAHAM RICHARD ASVP, Development
|
Tax withholdingOrdinary Shares | 6,598 | $18.22 | $120,215.56 |
DisclosureSEC source: 0001179110-20-009261 · edgar.xml · nonDerivative · entry 1 GRAHAM RICHARD A · CIK 0001820036 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,625 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:19 UTC |
BRADY ANNPresident, TBIL
|
Tax withholdingOrdinary Shares | 2,292 | $18.22 | $41,760.24 |
DisclosureSEC source: 0001179110-20-009259 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,579 Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 21:05 UTC |
Hindman Andrew A.SVP, Chief Financial Officer
|
GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008540 · edgar.xml · nonDerivative · entry 1 Hindman Andrew A. · CIK 0001607965 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,458 F1 · shares: On July 1 2019, the reporting person was granted a performance stock unit award that vests based on the achievement of certain performance conditions over a three-year timeframe from 2019 through June 30, 2022 and continued employment. On July 27, 2020, the performance conditions applicable to 20,000 shares were achieved and such shares will vest on August 20, 2021, subject to the reporting person's continued service. F2 · balance_after: Includes 968 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC |
PAKIANATHAN DEEPIKADirector
|
GrantShare Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $20.66 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · derivative · entry 3 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires 2020-06-30 F2 · derivative.exercise_date: This option shall vest monthly over ten months of service from the date of grant and will vest in full upon the earlier of the ten-month anniversary of Dr. Pakianathan's appointment to the Board or the date of the Company's 2021 annual meeting of shareholders. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC |
PAKIANATHAN DEEPIKADirector
|
GrantShare Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $20.66 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · derivative · entry 2 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option vests monthly over 24 months of service from the date of grant. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:53 UTC |
PAKIANATHAN DEEPIKADirector
|
GrantOrdinary Shares | 8,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008053 · edgar.xml · nonDerivative · entry 1 PAKIANATHAN DEEPIKA · CIK 0001270734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,067 Read SEC document |
| June 22, 2020 Filed Jun 22, 2020 21:29 UTC |
GSK plc10% owner
|
SaleExchangeable Note · Derivative | Not disclosed | Not disclosed Strike: $29.07 | $280,336,000.00 |
DisclosureSEC source: 0001387131-20-005871 · tbph-form4_062220.xml · derivative · entry 1 GLAXOSMITHKLINE PLC · CIK 0001131399 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Ordinary Shares · 9,644,792 shares Expires not disclosed F1 · kind: On June 22, 2020, GSK Finance No.3 plc ("GSK Finance"), a wholly owned indirect subsidiary of GlaxoSmithKline plc ("GSK"), issued $280,336,000 of its senior notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma"). The Ordinary Shares are held directly by GSK Finance. F2 · price: The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds. F2 · derivative.exercise_date: The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds. F1 · derivative.expiration_date: On June 22, 2020, GSK Finance No.3 plc ("GSK Finance"), a wholly owned indirect subsidiary of GlaxoSmithKline plc ("GSK"), issued $280,336,000 of its senior notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma"). The Ordinary Shares are held directly by GSK Finance. F1 · ownership.nature: On June 22, 2020, GSK Finance No.3 plc ("GSK Finance"), a wholly owned indirect subsidiary of GlaxoSmithKline plc ("GSK"), issued $280,336,000 of its senior notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma"). The Ordinary Shares are held directly by GSK Finance. Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:14 UTC |
WORBOYS PHILIP DSVP, Research & Transl Science
|
Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006538 · edgar.xml · nonDerivative · entry 1 WORBOYS PHILIP D · CIK 0001668718 · SVP, Research & Transl Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,355 F1 · balance_after: Includes 412 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:09 UTC |
PITZER KENNETH RSVP, Prod Strat & Comm Plng
|
Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006528 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,891 Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:11 UTC |
Shafer Bradford JEVP, Gen. Counsel, Secretary
|
Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006532 · edgar.xml · nonDerivative · entry 1 Shafer Bradford J · CIK 0001302448 · EVP, Gen. Counsel, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,527 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:13 UTC |
Winningham Rick EDirector · Chief Executive Officer
|
Tax withholdingOrdinary Shares | 13,946 | $26.67 | $371,939.82 |
DisclosureSEC source: 0001179110-20-006535 · edgar.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,061 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:10 UTC |
SABESAN VIJAYSVP, Technical Operations
|
Tax withholdingOrdinary Shares | 3,801 | $26.67 | $101,372.67 |
DisclosureSEC source: 0001179110-20-006530 · edgar.xml · nonDerivative · entry 1 SABESAN VIJAY · CIK 0001767807 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,641 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:07 UTC |
PASQUALONE FRANKSVP, Chief Comm Ops Officer
|
Tax withholdingOrdinary Shares | 4,214 | $26.67 | $112,387.38 |
DisclosureSEC source: 0001179110-20-006526 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,108 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:06 UTC |
HAUMANN BRETT KSVP Clin Dev & Chief Med Ofc
|
Tax withholdingOrdinary Shares | 4,212 | $26.67 | $112,334.04 |
DisclosureSEC source: 0001179110-20-006524 · edgar.xml · nonDerivative · entry 1 HAUMANN BRETT K · CIK 0001607733 · SVP Clin Dev & Chief Med Ofc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,456 Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:05 UTC |
BRADY ANNPresident, TBIL
|
Tax withholdingOrdinary Shares | 2,292 | $26.67 | $61,127.64 |
DisclosureSEC source: 0001179110-20-006521 · edgar.xml · nonDerivative · entry 1 BRADY ANN · CIK 0001767974 · President, TBIL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,871 Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:53 UTC |
Gunderson Robert V JRDirector
|
GrantShare Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001179110-20-005297 · edgar.xml · derivative · entry 3 Gunderson Robert V JR · CIK 0001302450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 6,000 shares Expires 2030-04-27 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's shareholders provided the optionee remains in continuous service on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:53 UTC |
Gunderson Robert V JRDirector
|
GrantOrdinary Shares | 6,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005297 · edgar.xml · nonDerivative · entry 1 Gunderson Robert V JR · CIK 0001302450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,265 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.